Patents by Inventor Jack Singer
Jack Singer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8748577Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.Type: GrantFiled: January 31, 2012Date of Patent: June 10, 2014Assignee: Cell Therapeutics, Inc.Inventors: Marc Besman, Stewart Chipman, David Leung, Jack Singer
-
Publication number: 20120252717Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.Type: ApplicationFiled: January 31, 2012Publication date: October 4, 2012Applicant: CELL THERAPEUTICS, INC.Inventors: Marc Besman, Stewart Chipman, David Leung, Jack Singer
-
Patent number: 8129348Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.Type: GrantFiled: October 14, 2008Date of Patent: March 6, 2012Assignee: Cell Therapeutics, Inc.Inventors: Marc Besman, Stewart Chipman, David Leung, Jack Singer
-
Publication number: 20090298762Abstract: Disclosed are biologically active protein conjugates that comprise a biologically active polypeptide coupled via a peptide bond to a polypeptide comprising from 2 to about 500 units of a repeating peptide motif, wherein the biologically active protein conjugate exhibits a modified plasma half-life compared to the intrinsic half-life of the unconjugated biologically active polypeptide or protein. Also disclosed are methods of making and using the conjugated proteins, as well as methods for determining whether a given conjugate exhibits a modified half life relative to the intrinsic half life of the unconjugated polypeptide.Type: ApplicationFiled: October 14, 2008Publication date: December 3, 2009Applicant: Cell Therapeutics, Inc.Inventors: Marc Besman, Stewart Chipman, David Leung, Jack Singer
-
Publication number: 20070167349Abstract: Disclosed are methods for selecting a treatment for, and then treating various types of cancers in males and females, comprising delivery of an anti-cancer drug conjugated to a poly (amino acid) polymer, optionally in combination with estrogen therapy.Type: ApplicationFiled: December 5, 2006Publication date: July 19, 2007Applicant: Cell Therapeutics, Inc.Inventor: Jack Singer
-
Publication number: 20050148600Abstract: Methods are provided for treating or preventing obesity by inhibiting the activity of lysophosphatidic acyltransferase ? (LPAAT-?).Type: ApplicationFiled: August 25, 2004Publication date: July 7, 2005Inventor: Jack Singer
-
Publication number: 20030033011Abstract: An intraocular lens (IOL) corrects vision disorders and prevents the formation of cataracts. The IOL can be inserted in the anterior or posterior chamber of the eye, or can be iris-fixated. The IOL can correct for myopia, hyperopia, presbyopia and/or astigmatism. Additionally, the IOL contains an ultraviolet radiation (UVR) blocker, that absorbs UVR in the 300-400 nm range. The absorption of the UVR allows the IOL to reduce or eliminate cataract formation.Type: ApplicationFiled: August 8, 2001Publication date: February 13, 2003Inventors: Jack A. Singer, Joe Kiernan
-
Patent number: 5965564Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: March 20, 1998Date of Patent: October 12, 1999Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5792772Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: June 1, 1995Date of Patent: August 11, 1998Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5739138Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: June 1, 1995Date of Patent: April 14, 1998Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5652243Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: November 22, 1994Date of Patent: July 29, 1997Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Jack Singer
-
Patent number: 5648357Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: September 16, 1994Date of Patent: July 15, 1997Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5629315Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: June 1, 1995Date of Patent: May 13, 1997Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5621102Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: June 1, 1995Date of Patent: April 15, 1997Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5620984Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating inflammatory disease.Type: GrantFiled: June 1, 1995Date of Patent: April 15, 1997Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5612349Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.Type: GrantFiled: June 1, 1995Date of Patent: March 18, 1997Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5580874Abstract: Them is disclosed compounds and pharmaceutical compositions that is R enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating the side effects of immunosuppressive agent and interleukin-2 therapy.Type: GrantFiled: June 1, 1995Date of Patent: December 3, 1996Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5580873Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating proliferative vascular disease.Type: GrantFiled: June 1, 1995Date of Patent: December 3, 1996Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 5567704Abstract: There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in treating baldness.Type: GrantFiled: June 1, 1995Date of Patent: October 22, 1996Assignee: Cell Therapeutics, Inc.Inventors: James A. Bianco, Paul Woodson, David Porubek, Jack Singer
-
Patent number: 4593031Abstract: This invention relates to a composition and method for potentiating the antidepressant effect of dibenzocycloheptadiene-type antidepressant agents, for example, nortriptyline, in the treatment of depression, especially geriatric depression, by administering them in combination with an approximately 1:1:1 by weight mixture of dihydroergocryptine (2:1 .alpha.:.beta.), dihydroergocornine and dihydroergocristine.Type: GrantFiled: June 5, 1985Date of Patent: June 3, 1986Assignee: Sandoz, Inc.Inventors: Robert W. Griffith, Jack Singer